BeOne Medicines Ltd (HK:6160)
:6160
Want to see HK:6160 full AI Analyst Report?
6160 Stock Chart & Stats
HK$193.20
HK$5.50(5.26%)
At close: 4:00 PM EST
HK$193.20
HK$5.50(5.26%)
Day’s Range― - ―
52-Week RangeHK$142.10 - HK$229.40
Previous CloseN/A
Volume1.62M
Average Volume (3M)5.08M
Market Cap
HK$270.07B
Enterprise ValueHK$28.75B
Total Cash (Recent Filing)HK$4.83B
Total Debt (Recent Filing)HK$2.05B
Price to Earnings (P/E)34.8
Beta0.93
Next Earnings
Aug 21, 2026EPS Estimate
0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding1,426,363,900
10 Day Avg. Volume3,608,600
30 Day Avg. Volume5,076,742
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)7.49
Price to Sales (P/S)6.10
P/FCF Ratio34.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$253.58Price Target Upside31.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)3.94
Revenue Forecast (FY)HK$50.69B
Bulls Say, Bears Say
Bulls Say
High And Sustainable MarginsAn ~87% gross margin and ~12% EBIT margin indicate durable product-level pricing power and efficient cost structure. Such margins support reinvestment in R&D and commercial expansion, and provide a structural buffer against cyclical revenue swings, aiding long-term profitability.
Strong Cash GenerationRobust OCF and ~1.10B FCF with 27% FCF growth show the business converts earnings into cash consistently. This durable cash generation reduces reliance on external financing, funds pipeline development and commercialization, and supports strategic flexibility over multiple quarters.
Regulatory Momentum For PipelinePriority Review and Breakthrough Therapy designations are structural catalysts: they shorten timelines and signal clinical/regulatory validation. Such durable regulatory progress can expand the addressable market and strengthen long-term product mix and revenue diversification beyond core products.
Bears Say
Slowing Revenue GrowthA shift from earlier hyper-growth to ~7% TTM growth indicates the company is moving into a steadier growth phase. Structurally, this raises the bar for sustaining investor expectations and increases dependence on product lifecycle management, new approvals, and international expansion to drive long-term top-line gains.
Rising LeverageMaterial debt growth increases financial risk and reduces balance-sheet flexibility. If margins or cash conversion weaken, higher leverage could constrain the company’s ability to invest in R&D or commercial programs and heighten sensitivity to interest costs over the medium term.
Imperfect Cash ConversionOCF covering a fraction of accounting EBIT points to working-capital or timing drags. Structurally inconsistent cash conversion can create funding volatility for R&D and commercialization spending, increasing the need for careful cash management especially if revenue growth softens.
BeOne Medicines Ltd News
6160 FAQ
What was BeOne Medicines Ltd’s price range in the past 12 months?
BeOne Medicines Ltd lowest stock price was HK$142.10 and its highest was HK$229.40 in the past 12 months.
What is BeOne Medicines Ltd’s market cap?
BeOne Medicines Ltd’s market cap is HK$270.07B.
When is BeOne Medicines Ltd’s upcoming earnings report date?
BeOne Medicines Ltd’s upcoming earnings report date is Aug 21, 2026 which is in 90 days.
How were BeOne Medicines Ltd’s earnings last quarter?
BeOne Medicines Ltd released its earnings results on May 06, 2026. The company reported HK$1.181 earnings per share for the quarter, beating the consensus estimate of HK$0.926 by HK$0.255.
Is BeOne Medicines Ltd overvalued?
According to Wall Street analysts BeOne Medicines Ltd’s price is currently Undervalued.
Does BeOne Medicines Ltd pay dividends?
BeOne Medicines Ltd does not currently pay dividends.
What is BeOne Medicines Ltd’s EPS estimate?
BeOne Medicines Ltd’s EPS estimate is 0.94.
How many shares outstanding does BeOne Medicines Ltd have?
BeOne Medicines Ltd has 1,426,363,900 shares outstanding.
What happened to BeOne Medicines Ltd’s price movement after its last earnings report?
BeOne Medicines Ltd reported an EPS of HK$1.181 in its last earnings report, beating expectations of HK$0.926. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of BeOne Medicines Ltd?
Currently, no hedge funds are holding shares in HK:6160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$253.58 (31.25% Upside)
HK$253.58 (31.25% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.37%
12-Months-Change
Fundamentals
Return on Equity
12.04%
Trailing 12-Months
Asset Growth
47.56%
Trailing 12-Months
Company Description
BeOne Medicines Ltd
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
6160 Stock 12 Month Forecast
Average Price Target
HK$253.58
▲(31.25% Upside)
Technical Analysis
Innovent Biologics
―
Wuxi Biologics (Cayman)
―
WuXi AppTec Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
―
Options Prices
Currently, No data available
---